

10/526,178

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS	7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS	8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS	9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	13	OCT 19	E-mail format enhanced
NEWS	14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS	20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	21	NOV 13	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	22	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	23	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS	24	NOV 20	CA/CAplus patent kind codes will be updated
NEWS	25	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	26	DEC 11	CAS REGISTRY chemical nomenclature enhanced

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that

10/526,178

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:14:46 ON 12 DEC 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 18:15:02 ON 12 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 DEC 2006 HIGHEST RN 915185-72-7

DICTIONARY FILE UPDATES: 11 DEC 2006 HIGHEST RN 915185-72-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10526178.str

10/526,178



chain nodes :

9 10 11 12 13 14

ring nodes :

1 2 3 4 5 6 15 16 17 18 19 20

chain bonds :

1-9 9-10 9-11 10-12 12-13 13-14 13-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20

exact/norm bonds :

1-2 1-6 1-9 2-3 3-4 4-5 5-6 9-10 9-11 10-12 13-14 13-15 15-16 15-20
16-17 17-18 18-19 19-20

exact bonds :

12-13

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 9:CLASS 10:CLASS 11:CLASS
12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom


L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

10/526,178



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 18:15:24 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 86 TO ITERATE

100.0% PROCESSED 86 ITERATIONS

14 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 1164 TO 2276

PROJECTED ANSWERS: 56 TO 504

L2 14 SEA SSS SAM L1

=> d scan


10/526,178

L2 14 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 1-Piperazinecarboxamide, N-[2-[4-cyclohexyl-4-[[1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-(2-methylpropyl)-4-(phenylmethyl)-, monohydrochloride, (2S)-(9CI)

MF C41 H60 F N5 O3 . Cl H

Absolute stereochemistry.




● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):13

10/526,178

L2 14 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Pyrido[1,2-a]pyrazine-2-carboxamide, N-[2-[4-cyclohexyl-4-[[1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]octahydro-, monohydrochloride, (9aR)- (9CI)
MF C34 H52 F N5 O3 . Cl H

Absolute stereochemistry.




● HCl

10/526,178

L2 14 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-2-[[(3,5-dimethyl-1-piperazinyl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, 1-methylethyl ester (9CI)
MF C31 H47 F N4 O4
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/526,178


L2 14 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[3-(4-fluorophenyl)-2-[[[(3R)-3-(1-methylethyl)-1-piperazinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester
(9CI)

MF C31 H47 F N4 O4

CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10/526,178

L2 14 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[(2-methoxy-1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl-, monohydrochloride (9CI)

MF C35 H56 F N5 O4 . Cl H


Absolute stereochemistry.



10/526,178

L2 14 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[3-(4-fluorophenyl)-2-[[[(9aR)-
octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]carbonyl]amino]-1-oxopropyl]-,
1-methylethyl ester (9CI)
MF C33 H49 F N4 O4
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10/526,178

L2 14 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 1-Piperazinecarboxylic acid, 4-[[[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]amino]carbonyl]-2-ethyl-, 1,1-dimethylethyl ester, monohydrochloride, (2S)- (9CI)

MF C37 H58 F N5 O5 . Cl H

Absolute stereochemistry.




● HCl

10/526,178

L2 14 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-3-(4-fluorophenyl)-1-oxo-
2-[[[(2,3,5,6-tetramethyl-1-piperazinyl)carbonyl]amino]propyl]-,
tetrahydro-2H-pyran-4-yl ester, monohydrochloride (9CI)
MF C35 H53 F N4 O5 . Cl H


Absolute stereochemistry.



10/526,178

L2 14 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-
3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(3-
methoxyphenyl)- (9CI)
MF C36 H43 Cl N6 O3
CI COM .

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/526,178

L2 14 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-3-(4-fluorophenyl)-2-
[[[(3R)-3-(1-methylethyl)-1-piperazinyl]carbonyl]amino]-1-oxopropyl]-,
ethyl ester, monohydrochloride (9CI)
MF C31 H47 F N4 O4 . Cl H

Absolute stereochemistry.



● HCl

10/526,178


L2 14 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[3-(4-fluorophenyl)-2-[[[(9aS)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]carbonyl]amino]-1-oxopropyl]-, 1-methylethyl ester (9CI)

MF C33 H49 F N4 O4

CI COM

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/526,178

L2 14 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 1-Piperazinecarboxamide, N-[2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,3-dimethyl-, monohydrochloride (9CI)


MF C32 H50 F N5 O3 . Cl H



● HCl

10/526,178

L2 14 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-[[1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-2-oxoethyl]-5-methyl- (9CI)
MF C32 H48 Cl N5 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10/526,178

L2 14 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 1-Piperazinecarboxamide, N-[(1R)-2-[4-[[bis(1-methylethyl)amino]carbonyl]-4-cyclohexyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl-, monohydrochloride (9CI)

MF C34 H54 F N5 O3 . Cl H

Absolute stereochemistry.



● HCl

ALL ANSWERS HAVE BEEN SCANNED

10/526,178

=> s l1 sss ful

FULL SEARCH INITIATED 18:15:44 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1601 TO ITERATE

100.0% PROCESSED 1601 ITERATIONS

347 ANSWERS

SEARCH TIME: 00.00.01

L3 347 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 18:15:48 ON 12 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Dec 2006 VOL 145 ISS 25

FILE LAST UPDATED: 11 Dec 2006 (20061211/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 10 L3

=> d l4 1-10 bib hitstr

10/526,178

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:1030512 CAPLUS
DN 145:397555
TI Preparation of tetrahydrobenzo[e][1,4]diazepine derivatives as V2 receptor agonists
IN Suzuki, Ritsu; Yokoyama, Kenji; Kondo, Tatsuhiko; Hirasawa, Hideaki; Kambara, Mikie; Kobayashi, Hiroaki
PA Kissei Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 237pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006104008	A1	20061005	WO 2006-JP305820	20060323
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI JP 2005-90221 A 20050325

OS MARPAT 145:397555

IT 911309-91-6P 911312-39-5P 911312-59-9P
911312-60-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of tetrahydrobenzo[e][1,4]diazepine derivs. as V2 receptor agonists for treatment of central diabetes insipidus, night frequent urination, etc.)

RN 911309-91-6 CAPLUS

CN 4H-1,4-Benzodiazepine-4-carboxamide, 1-[2-chloro-4-(1H-pyrazol-1-yl)benzoyl]-1,2,3,5-tetrahydro-3-methyl-N-[2-oxo-2-(1-piperidinyl)ethyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/526,178



RN 911312-39-5 CAPLUS

CN 4H-1,4-Benzodiazepine-4-carboxamide, 1-(2-chloro-4-ethoxybenzoyl)-1,2,3,5-tetrahydro-N-[2-(4-hydroxy-1-piperidiny)-2-oxoethyl]-3-methyl-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911312-59-9 CAPLUS

CN 4H-1,4-Benzodiazepine-4-carboxamide, 1-(2-chloro-4-ethoxybenzoyl)-1,2,3,5-tetrahydro-N-[2-(4-methoxy-1-piperidiny)-2-oxoethyl]-3-methyl-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/526,178



RN 911312-60-2 CAPLUS

CN 4H-1,4-Benzodiazepine-4-carboxamide, 1-(2-chloro-4-ethoxybenzoyl)-N-[2-(4-ethoxy-1-piperidiny)-2-oxoethyl]-1,2,3,5-tetrahydro-3-methyl-, (3R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.





RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/526,178

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:453183 CAPLUS
DN 141:23903
TI Preparation of indole amino acid derivatives as somatostatin agonists or antagonists
IN Abe, Hidenori; Matsunaga, Shinichiro; Takekawa, Shiro; Watanabe, Masanori
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 482 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004046107	A1	20040603	WO 2003-JP14622	20031118
	WO 2004046107	C1	20050616		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2506735	AA	20040603	CA 2003-2506735	20031118
	AU 2003280838	A1	20040615	AU 2003-280838	20031118
	JP 2004300133	A2	20041028	JP 2003-388524	20031118
	EP 1562898	A1	20050817	EP 2003-772841	20031118
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	CN 1738798	A	20060222	CN 2003-80108633	20031118
	US 2006223826	A1	20061005	US 2005-534725	20050512
PRAI	JP 2002-335661	A	20021119		
	JP 2003-76435	A	20030319		
	WO 2003-JP14622	W	20031118		
OS	MARPAT 141:23903				
IT	697306-82-4P 697306-83-5P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation of indole amino acid derivs. as somatostatin agonists or antagonists)				
RN	697306-82-4 CAPLUS				
CN	1-Piperazinecarboxamide, N-[(1R,2S)-1-[[7-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-fluorophenyl)-(9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RN 697306-83-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R,2S)-1-[[7-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/526,178




10/526,178

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:252507 CAPLUS
DN 140:287409
TI Preparation of carbamoylpiperazines as melanocortin-4 receptor agonists
IN Bakshi, Raman Kumar; Nargund, Ravi P.; Palucki, Brenda L.; Park, Min K.;
Ye, Zhixiong
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 154 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

Applicants'

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004024720	A1	20040325	WO 2003-US27892	20030905
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2498272	AA	20040325	CA 2003-2498272	20030905
	AU 2003268493	A1	20040430	AU 2003-268493	20030905
	EP 1539735	A1	20050615	EP 2003-749459	20030905
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2006505531	T2	20060216	JP 2004-536116	20030905
	US 2006040906	A1	20060223	US 2005-526178	20050228
PRAI	US 2002-409879P	P	20020911		
	WO 2003-US27892	W	20030905		
OS	MARPAT 140:287409				
IT	674791-30-1P 674791-38-9P 674791-48-1P 674791-50-5P 674791-54-9P 674792-30-4P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of carbamoylpiperazines as melanocortin-4 receptor agonists)				
RN	674791-30-1 CAPLUS				
CN	1-Piperazinecarboxylic acid, 4-[[[2-[4-cyclohexyl-4-(ethoxycarbonyl)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]amino]carbonyl]-2-(1-methylethyl)-, 1,1-dimethylethyl ester, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



● HCl

RN 674791-38-9 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid, 5-[[[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 674791-48-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-3-(1-methylethyl)-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/526,178



RN 674791-50-5 CAPLUS


CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 674791-54-9 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)

10/526,178




RN 674792-30-4 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 674791-50-5


CMF C31 H46 F N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 674790-45-5P 674790-46-6P 674790-47-7P

674790-48-8P 674790-49-9P 674790-50-2P
674790-51-3P 674790-52-4P 674790-53-5P
674790-54-6P 674790-55-7P 674790-56-8P
674790-57-9P 674790-58-0P 674790-59-1P
674790-60-4P 674790-61-5P 674790-62-6P
674790-63-7P 674790-64-8P 674790-65-9P
674790-66-0P 674790-67-1P 674790-68-2P
674790-69-3P 674790-70-6P 674790-71-7P
674790-72-8P 674790-73-9P 674790-74-0P
674790-75-1P 674790-76-2P 674790-77-3P
674790-78-4P 674790-79-5P 674790-80-8P
674790-81-9P 674790-82-0P 674790-83-1P
674790-84-2P 674790-85-3P 674790-86-4P
674790-87-5P 674790-88-6P 674790-89-7P
674790-90-0P 674790-91-1P 674790-92-2P
674790-93-3P 674790-94-4P 674790-95-5P
674790-96-6P 674790-97-7P 674790-98-8P
674790-99-9P 674791-00-5P 674791-01-6P
674791-02-7P 674791-03-8P 674791-04-9P
674791-05-0P 674791-06-1P 674791-07-2P
674791-08-3P 674791-09-4P 674791-10-7P
674791-11-8P 674791-12-9P 674791-13-0P
674791-14-1P 674791-15-2P 674791-16-3P
674791-17-4P 674791-18-5P 674791-19-6P
674791-20-9P 674791-21-0P 674791-22-1P
674791-23-2P 674791-24-3P 674791-25-4P
674791-26-5P 674791-27-6P 674791-28-7P
674791-29-8P 674791-31-2P 674791-32-3P
674791-33-4P 674791-34-5P 674791-35-6P
674791-36-7P 674791-37-8P 674791-39-0P
674791-40-3P 674791-41-4P 674791-43-6P
674791-44-7P 674791-45-8P 674791-46-9P
674791-47-0P 674791-49-2P 674791-51-6P
674791-52-7P 674791-53-8P 674791-55-0P
674791-56-1P 674791-58-3P 674791-59-4P
674791-60-7P 674791-61-8P 674791-63-0P
674791-65-2P 674791-67-4P 674791-68-5P
674792-28-0P 674792-31-5P 674792-32-6P
674792-33-7P 674792-34-8P 674792-35-9P
674792-36-0P 674792-37-1P 674792-38-2P
674792-39-3P 674792-40-6P 674792-41-7P
674792-42-8P 674792-43-9P 674792-44-0P
674792-45-1P 674792-46-2P 674792-47-3P
674792-48-4P 674792-49-5P 674792-50-8P
674792-51-9P 674792-52-0P 674792-53-1P
674792-54-2P 674792-55-3P 674792-56-4P
674792-57-5P 674792-58-6P 674792-59-7P
674792-60-0P 674792-61-1P 674792-62-2P
674792-63-3P 674792-64-4P 674792-66-6P
674792-68-8P 674792-70-2P 674792-72-4P
674792-73-5P 674792-75-7P 674792-77-9P
674792-78-0P 674792-79-1P 674792-80-4P
674792-81-5P 674792-82-6P 674792-83-7P
674792-85-9P 674792-86-0P 674792-87-1P
674792-88-2P 674792-89-3P 674792-90-6P
674792-91-7P 674792-92-8P 674792-93-9P
674792-94-0P 674792-96-2P 674792-98-4P
674792-99-5P 674793-00-1P 674793-03-4P
674793-05-6P 674793-07-8P 674793-09-0P
674793-11-4P 674793-13-6P 674793-16-9P
674793-18-1P 674793-20-5P 674793-22-7P

10/526,178

674793-24-9P 674798-14-2P 675832-45-8P
675832-46-9P 675832-47-0P 675832-48-1P
675832-49-2P 675832-50-5P 675832-51-6P
675832-52-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of carbamoylpiperazines as melanocortin-4 receptor agonists)

RN 674790-45-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-
dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-
oxoethyl]-3,5-dimethyl-, monohydrochloride, (3R,5S)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




● HCl

RN 674790-46-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-(7-azabicyclo[2.2.1]hept-7-
ylcarbonyl)-4-cyclohexyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-
oxoethyl]-3,5-dimethyl-, monohydrochloride, (3R,5S)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.


10/526,178



RN 674790-47-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(3,3-dimethyl-2-oxo-1-azetidiny)methyl]-1-piperidinyl]-1-[4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-48-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-1-piperidinyl]-1-[4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/526,178



RN 674790-49-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-2-[[(3,5-dimethyl-1-piperazinyl) carbonyl] amino]-3-(4-fluorophenyl)-1-oxopropyl]-, tetrahydro-2H-pyran-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674790-50-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-(7-azabicyclo[2.2.1]hept-7-ylcarbonyl)-4-cyclohexyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674790-51-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(diethylamino)carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 674790-52-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(diethylamino)carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/526,178




● HCl

RN 674790-53-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-(3-fluoro-3-methylbutyl)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-54-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[2-(1-hydroxycyclopropyl)ethyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/526,178




● HCl

RN 674790-55-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[2-(1-fluorocyclopropyl)ethyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-56-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[2-(1-fluorocyclopropyl)ethyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/526,178




● HCl

RN 674790-57-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-(3-fluoro-3-methylbutyl)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-58-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-2-[[3,5-diethyl-1-piperazinyl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, tetrahydro-2H-pyran-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/526,178



RN 674790-59-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 674790-60-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-2-[[[(3,5-dimethyl-1-piperazinyl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/526,178




● HCl

RN 674790-61-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-2-[[(3,5-diethyl-1-piperazinyl) carbonyl] amino]-3-(4-fluorophenyl)-1-oxopropyl]-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-62-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl) amino] carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl) methyl]-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/526,178




● HCl

RN 674790-63-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-[[bis(1-methylethyl)amino]carbonyl]-4-cyclohexyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-64-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(5,5-dimethyl-1,1-dioxido-2-isothiazolidinyl)methyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/526,178



RN 674790-65-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[(2-methoxy-1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674790-66-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-[[bis(1-methylethyl)amino]carbonyl]-4-cyclohexyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-67-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(2-methoxy-1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-68-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-[[bis(1-methylethyl)amino]carbonyl]-4-cyclohexyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl-, monohydrochloride, (3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/526,178



● HCl

RN 674790-69-3 CAPLUS
 CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl-, monohydrochloride, (3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-70-6 CAPLUS
 CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-2-[[[(3R,5R)-3,5-dimethyl-1-piperazinyl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/526,178




● HCl

RN 674790-71-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl-, monohydrochloride, (3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-72-8 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]hexahydro-3,5-dimethyl-, monohydrochloride, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/526,178




● HCl

RN 674790-73-9 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]hexahydro-3,5-dimethyl-, monohydrochloride, (3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-74-0 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[(1R)-2-[4-[[bis(1-methylethyl)amino]carbonyl]-4-cyclohexyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]hexahydro-3,5-dimethyl-, monohydrochloride, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/526,178




● HCl

RN 674790-75-1 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[(1R)-2-[4-[[bis(1-methylethyl)amino]carbonyl]-4-cyclohexyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]hexahydro-3,5-dimethyl-, monohydrochloride, (3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-76-2 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-ethylhexahydro-3-methyl-, monohydrochloride, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/526,178




● HCl

RN 674790-79-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,3,5-trimethyl-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-80-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,3,5-trimethyl-, monohydrochloride, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-81-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-(1-methylethyl)-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-82-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-3-(4-fluorophenyl)-2-[[[(2R)-2-(1-methylethyl)-1-piperazinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-83-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-(1-methylethyl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-84-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-3-(4-fluorophenyl)-2-[[[(2S)-2-(1-methylethyl)-1-piperazinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/526,178




● HCl

RN 674790-85-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-ethyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-86-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-(2-methylpropyl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-87-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-88-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2,2-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-89-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3-(1-methylethyl)-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-90-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-3-(4-fluorophenyl)-2-[[[(3R)-3-(1-methylethyl)-1-piperazinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-91-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3-(1-methylethyl)-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-92-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-3-(4-fluorophenyl)-2-[[[(3S)-3-(1-methylethyl)-1-piperazinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-93-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-3-(1-methylethyl)-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-94-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3-ethyl-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-95-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3-(2-methylpropyl)-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-96-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3-methyl-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-97-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-98-8 CAPLUS

CN 4,7-Diazaspiro[2.5]octane-7-carboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674790-99-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(2R)-2-[[[3,5-dimethyl-1-piperazinyl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-4-(1-ethylpropyl)-, tetrahydro-2H-pyran-4-yl ester, monohydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-00-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-[[bis(1-methylethyl)amino]carbonyl]-4-phenyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-01-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-2-oxoethyl]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-02-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(2R)-3-(4-chlorophenyl)-2-[[[(3,5-dimethyl-1-piperazinyl)carbonyl]amino]-1-oxopropyl]-4-cyclohexyl-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-03-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(2R)-2-[[[(3R,5R)-3,5-dimethyl-1-piperazinyl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-4-(1-ethylpropyl)-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-04-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(2R)-2-[[[(3,5-diethyl-1-piperazinyl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-4-(1-ethylpropyl)-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-05-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-06-1 CAPLUS

CN Pyrrolo[1,2-a]pyrazine-2(1H)-carboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 674791-07-2 CAPLUS
 CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 674791-08-3 CAPLUS
 CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-09-4 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-[[1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-10-7 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-[[1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-2-oxoethyl]-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-11-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-2-[(2,5-diazabicyclo[2.2.1]hept-2-ylcarbonyl)amino]-3-(4-fluorophenyl)-1-oxopropyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-12-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(2R)-3-(4-chlorophenyl)-2-[(2,5-diazabicyclo[2.2.1]hept-2-ylcarbonyl)amino]-1-oxopropyl]-4-cyclohexyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-13-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[2-[4-cyclohexyl-4-[[(1,1-dimethylethyl) amino] carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-(1-methylethyl)-4-(phenylmethyl)-, monohydrochloride, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-14-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[3-(4-fluorophenyl)-2-[[[(2R)-2-(1-methylethyl)-4-(phenylmethyl)-1-piperazinyl] carbonyl] amino]-1-oxopropyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-15-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[2-[4-cyclohexyl-4-[[(1,1-dimethylethyl) amino] carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-(1-methylethyl)-4-(phenylmethyl)-, monohydrochloride, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-16-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[3-(4-fluorophenyl)-2-[[[(2S)-2-(1-methylethyl)-4-(phenylmethyl)-1-piperazinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-17-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-(2-methylpropyl)-4-(phenylmethyl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-18-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-ethyl-4-(phenylmethyl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-19-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-4-(phenylmethyl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 674791-20-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2,2-dimethyl-4-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 674791-21-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-2-carboxamide, N-[2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]octahydro-, (9aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674791-22-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[3-(4-fluorophenyl)-2-[[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]carbonyl]amino]-1-oxopropyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674791-23-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-2-carboxamide, N-[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]octahydro-, (9aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674791-24-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[3-(4-fluorophenyl)-2-[[[(9aS)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]carbonyl]amino]-1-oxopropyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674791-25-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-2-carboxamide, N-[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]octahydro-, monohydrochloride, (9aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-26-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[3-(4-fluorophenyl)-2-[[[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]carbonyl]amino]-1-oxopropyl]-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-27-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-2-carboxamide, N-[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]octahydro-, monohydrochloride, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-28-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[3-(4-fluorophenyl)-2-[[[(9aS)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]carbonyl]amino]-1-oxopropyl]-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-29-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]amino]carbonyl]-2-(1-methylethyl)-, 1,1-dimethylethyl ester, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-31-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]amino]carbonyl]-2-(1-methylethyl)-, 1,1-dimethylethyl ester, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-32-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[2-[4-cyclohexyl-4-(ethoxycarbonyl)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]amino]carbonyl]-2-(1-methylethyl)-, 1,1-dimethylethyl ester, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

10/526,178

Absolute stereochemistry.




● HCl

RN 674791-33-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]amino]carbonyl]-2-(2-methylpropyl)-, 1,1-dimethylethyl ester, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-34-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]amino]carbonyl]-2-ethyl-, 1,1-dimethylethyl ester, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-35-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]amino]carbonyl]-2-methyl-, 1,1-dimethylethyl ester, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-36-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]amino]carbonyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 674791-37-8 CAPLUS

CN 4,7-Diazaspiro[2.5]octane-4-carboxylic acid, 7-[[[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A






● HCl

RN 674791-39-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3-(1-methylethyl)-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-40-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[3-(4-fluorophenyl)-2-[[[(3R)-3-(1-methylethyl)-1-piperazinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-41-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3-(1-methylethyl)-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-43-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3-(2-methylpropyl)-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-44-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl) amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3-ethyl-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 674791-45-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl) amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3-methyl-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 674791-46-9 CAPLUS


CN 1-Piperazinecarboxamide, N-[2-[4-cyclohexyl-4-[[(1,1-dimethylethyl) amino] carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 674791-47-0 CAPLUS


CN 4,7-Diazaspiro[2.5]octane-7-carboxamide, N-[2-[4-cyclohexyl-4-[[(1,1-dimethylethyl) amino] carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 674791-49-2 CAPLUS


CN 1-Piperazinecarboxamide, N-[2-[4-cyclohexyl-4-[[1,1-dimethylethyl]amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-3-(1-methylethyl)-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 674791-51-6 CAPLUS


CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-[[1,1-dimethylethyl]amino]carbonyl]-1-piperidinyl]-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 674791-52-7 CAPLUS


CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[2-[(2,5-diazabicyclo[2.2.1]hept-2-ylcarbonyl)amino]-3-(4-fluorophenyl)-1-oxopropyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 674791-53-8 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[3-(4-chlorophenyl)-2-[(2,5-diazabicyclo[2.2.1]hept-2-ylcarbonyl)amino]-1-oxopropyl]-4-cyclohexyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 674791-55-0 CAPLUS


CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 674791-56-1 CAPLUS


CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 674791-58-3 CAPLUS


CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 674791-59-4 CAPLUS


CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-2-oxoethyl]-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 674791-60-7 CAPLUS


CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[3-(4-fluorophenyl)-2-[[5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]carbonyl]amino]-1-oxopropyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 674791-61-8 CAPLUS


CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[3-(4-fluorophenyl)-2-[[[5-(1-methylethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]carbonyl]amino]-1-oxopropyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 674791-63-0 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[3-(4-chlorophenyl)-2-[[5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]carbonyl]amino]-1-oxopropyl]-4-cyclohexyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 674791-65-2 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[3-(4-chlorophenyl)-2-[[[5-(1-methylethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]carbonyl]amino]-1-oxopropyl]-4-cyclohexyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 674791-67-4 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 674791-68-5 CAPLUS


CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-[(dimethylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 674792-28-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-31-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(3,3-dimethyl-2-oxo-1-azetidiny]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-32-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-33-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-34-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-2-[(3,5-dimethyl-1-piperazinyl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, tetrahydro-2H-pyran-4-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-35-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-(7-azabicyclo[2.2.1]hept-7-ylcarbonyl)-4-cyclohexyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-36-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(diethylamino)carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 674792-37-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(diethylamino)carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/526,178



RN 674792-38-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-(3-fluoro-3-methylbutyl)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry:




RN 674792-39-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[2-(1-hydroxycyclopropyl)ethyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/526,178



RN 674792-40-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[2-(1-fluorocyclopropyl)ethyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-41-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[2-(1-fluorocyclopropyl)ethyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-42-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-(3-fluoro-3-methylbutyl)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-43-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-2-[[3,5-diethyl-1-piperazinyl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, tetrahydro-2H-pyran-4-yl, ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-44-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-45-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-2-[[[(3,5-dimethyl-1-piperazinyl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-46-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-2-[[3,5-diethyl-1-piperazinyl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 674792-47-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[1,1-dimethylethyl]amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/526,178



RN 674792-48-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-[[bis(1-methylethyl)amino]carbonyl]-4-cyclohexyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-49-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(5,5-dimethyl-1,1-dioxido-2-isothiazolidinyl)methyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-50-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(2-methoxy-1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl-3,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-51-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-[[bis(1-methylethyl)amino]carbonyl]-4-cyclohexyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-52-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[2-methoxy-1,1-dimethylethyl]amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-53-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-[[bis(1-methylethyl)amino]carbonyl]-4-cyclohexyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl-, (3R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-54-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl-, (3R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-55-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-2-[[[(3R,5R)-3,5-dimethyl-1-piperazinyl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-56-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[1,1-dimethylethyl]amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl-, (3R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-57-5 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[1,1-dimethylethyl]amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]hexahydro-3,5-dimethyl-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-58-6 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]hexahydro-3,5-dimethyl-, (3R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-59-7 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[(1R)-2-[4-[[bis(1-methylethyl)amino]carbonyl]-4-cyclohexyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]hexahydro-3,5-dimethyl-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/526,178

RN 674792-60-0 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[(1R)-2-[4-[[bis(1-methylethyl)amino]carbonyl]-4-cyclohexyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]hexahydro-3,5-dimethyl-, (3R,5R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 674792-61-1 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-ethylhexahydro-3-methyl-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-62-2 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-ethylhexahydro-3-methyl-, (3R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-63-3 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-64-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,3,5-trimethyl-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-66-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,3,5-trimethyl-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-68-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-(1-methylethyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-70-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-3-(4-fluorophenyl)-2-[[[(2R)-2-(1-methylethyl)-1-piperazinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-72-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-(1-methylethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-73-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-3-(4-fluorophenyl)-2-[[[(2S)-2-(1-methylethyl)-1-piperazinyl]carbonyl]amino]-1-oxopropyl]-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-75-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-ethyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-77-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-(2-methylpropyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-78-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-79-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-80-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3-(1-methylethyl)-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-81-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-3-(4-fluorophenyl)-2-[[[(3R)-3-(1-methylethyl)-1-piperazinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-82-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3-(1-methylethyl)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-83-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-3-(4-fluorophenyl)-2-[[[(3S)-3-(1-methylethyl)-1-piperazinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-85-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-3-(1-methylethyl)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-86-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3-ethyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-87-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3-(2-methylpropyl)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-88-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-89-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,3-dimethyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-90-6 CAPLUS

CN 4,7-Diazaspiro[2.5]octane-7-carboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-91-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(2R)-2-[[[3,5-dimethyl-1-piperazinyl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-4-(1-ethylpropyl)-, tetrahydro-2H-pyran-4-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-92-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-[[bis(1-methylethyl)amino]carbonyl]-4-phenyl-1-piperidiny]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-93-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-[[[1,1-dimethylethyl]amino]carbonyl]-1-piperidiny]-2-oxoethyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-94-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(2R)-3-(4-chlorophenyl)-2-[(3,5-dimethyl-1-piperazinyl)carbonyl]amino]-1-oxopropyl]-4-cyclohexyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-96-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(2R)-2-[[[(3R,5R)-3,5-dimethyl-1-piperazinyl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-4-(1-ethylpropyl)-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-98-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(2R)-2-[[(3,5-diethyl-1-piperazinyl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-4-(1-ethylpropyl)-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674792-99-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674793-00-1 CAPLUS

CN Pyrrolo[1,2-a]pyrazine-2(1H)-carboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[1,1-dimethylethyl]amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674793-03-4 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[1,1-dimethylethyl]amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674793-05-6 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[4-fluorophenyl)methyl]-2-oxoethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674793-07-8 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-2-oxoethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674793-09-0 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-2-oxoethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674793-11-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-2-[(2,5-diazabicyclo[2.2.1]hept-2-ylcarbonyl)amino]-3-(4-fluorophenyl)-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674793-13-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(2R)-3-(4-chlorophenyl)-2-[(2,5-diazabicyclo[2.2.1]hept-2-ylcarbonyl)amino]-1-oxopropyl]-4-cyclohexyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 674793-16-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-

10/526,178

dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674793-18-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-2-[[[(3S,5R)-3,5-dimethyl-1-piperazinyl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674793-20-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-2-[[[(3S,5R)-3,5-dimethyl-1-piperazinyl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 674793-22-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-[[bis(1-methylethyl)amino]carbonyl]-4-cyclohexyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-dimethyl-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 674793-24-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-[[bis(1-methylethyl)amino]carbonyl]-4-cyclohexyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-3,5-diethyl-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/526,178



RN 674798-14-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[3-(4-fluorophenyl)-2-[[[(3S)-3-(1-methylethyl)-1-piperazinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 675832-45-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-3-(4-fluorophenyl)-1-oxo-2-[[2,3,5,6-tetramethyl-1-piperazinyl]carbonyl]amino]propyl]-, tetrahydro-2H-pyran-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 675832-46-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2,3,5,6-tetramethyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 675832-47-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-[[bis(1-methylethyl)amino]carbonyl]-4-cyclohexyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2,3,5,6-tetramethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 675832-48-1 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[4-fluorophenyl)methyl]-2-oxoethyl]-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 675832-49-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-cyclohexyl-1-[(2R)-3-(4-fluorophenyl)-1-oxo-2-[[(2,3,5,6-tetramethyl-1-piperazinyl)carbonyl]amino]propyl]-, tetrahydro-2H-pyran-4-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 675832-50-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2,3,5,6-tetramethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 675832-51-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[4-[[bis(1-methylethyl)amino]carbonyl]-4-cyclohexyl-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2,3,5,6-tetramethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 675832-52-7 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, N-[(1R)-2-[4-cyclohexyl-4-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[4-fluorophenyl)methyl]-2-oxoethyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:396877 CAPLUS

DN 138:401769

TI Preparation of [1-[3-(indol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinolin-3-ylmethyl]amine derivatives as somatostatin receptor binding inhibitors

IN Abe, Hidenori; Kasai, Shizuo; Takekawa, Shiro; Watanabe, Masanori

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 191 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003042204	A1	20030522	WO 2002-JP10800	20021017
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2003192682	A2	20030709	JP 2002-303222	20021017
	EP 1437351	A1	20040714	EP 2002-775363	20021017
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	US 2005245571	A1	20051103	US 2004-492420	20040412
PRAI	JP 2001-322897	A	20011019		
	WO 2002-JP10800	W	20021017		
OS	MARPAT 138:401769				
IT	528859-34-9P 528859-38-3P 528859-53-2P 528859-57-6P 528859-60-1P 528859-63-4P 528859-66-7P 528859-70-3P 528859-74-7P 528859-77-0P 528859-80-5P 528859-83-8P 528859-86-1P 528859-89-4P 528859-92-9P 528859-95-2P 528859-98-5P 528860-01-7P 528860-07-3P 528861-18-9P 528861-19-0P 528861-20-3P 528861-27-0P 528861-28-1P 528861-29-2P 528861-30-5P 528861-31-6P 528861-32-7P 528861-33-8P 528861-34-9P 528861-35-0P 528861-36-1P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(preparation of [[(indolylpropanoyl)tetrahydroquinolinyl]methyl]amine derivs. as somatostatin receptor binding inhibitors (agonists) for prevention or treatment of diabetes or diabetes complications)				
RN	528859-34-9 CAPLUS				
CN	1-Piperazinecarboxamide, N-[1-[[3-(6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-ethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)				

CM 1

CRN 528859-33-8

CMF C31 H41 Cl N6 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 528859-38-3 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[1-[[(3R)-6-chloro-3-
[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-
3-yl)propyl]hexahydro-4-methyl-, bis(trifluoroacetate) (9CI) (CA INDEX
NAME)


CM 1

CRN 528859-37-2

CMF C31 H41 Cl N6 O2

Absolute stereochemistry.


10/526,178



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 528859-53-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 528859-52-1

CMF C36 H40 Cl F3 N6 O2

Absolute stereochemistry.


10/526,178



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 528859-57-6 CAPLUS



CN 1-Piperazinecarboxamide, 4-(4-acetylphenyl)-N-[1-[[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-56-5

CMF C37 H43 Cl N6 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 528859-60-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(2-chlorophenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 528859-59-8

10/526,178

CMF C35 H40 Cl2 N6 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 528859-63-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(3-methoxyphenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 528859-62-3

CMF C36 H43 Cl N6 O3

Absolute stereochemistry.


10/526,178



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 528859-66-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(3-chlorophenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 528859-65-6

CMF C35 H40 Cl2 N6 O2

Absolute stereochemistry.


10/526,178



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 528859-70-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(2-methylphenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 528859-69-0

CMF C36 H43 Cl N6 O2

Absolute stereochemistry.


10/526,178



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 528859-74-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(2-ethoxyphenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 528859-73-6

CMF C37 H45 Cl N6 O3

Absolute stereochemistry.


10/526,178



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 528859-77-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(2-fluorophenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 528859-76-9

CMF C35 H40 Cl F N6 O2

Absolute stereochemistry.


10/526,178



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 528859-80-5 CAPLUS



CN 1-Piperazinecarboxamide, N-[1-[[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-chlorophenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-79-2

CMF C35 H40 Cl2 N6 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 528859-83-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-methoxyphenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 528859-82-7

10/526,178


CMF C36 H43 Cl N6 O3

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 528859-86-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-fluorophenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

10/526,178


CM 1

CRN 528859-85-0


CMF C35 H40 Cl F N6 O2

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 528859-89-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-

10/526,178


3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(3-methylphenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528859-88-3

CMF C36 H43 Cl N6 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 528859-92-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(phenylmethyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 528859-91-8

CMF C36 H43 Cl N6 O2

10/526,178


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 528859-95-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 528859-94-1

CMF C34 H40 Cl N7 O2

Absolute stereochemistry.


10/526,178



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 528859-98-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-phenyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 528859-97-4

CMF C35 H41 Cl N6 O2

Absolute stereochemistry.


10/526,178



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 528860-01-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(2-methoxyphenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 528860-00-6

CMF C36 H43 Cl N6 O3

Absolute stereochemistry.


10/526,178



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 528860-07-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(2-pyrimidinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 528860-06-2

CMF C33 H39 Cl N8 O2

Absolute stereochemistry.


10/526,178



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 528861-18-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-
[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-
3-yl)propyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 528861-19-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 528861-20-3 CAPLUS

CN 1-Piperazinecarboxamide, 4-benzoyl-N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 528861-27-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 528861-28-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(3-fluorobenzoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 528861-29-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-4-(2-fluorobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 528861-30-5 CAPLUS

CN 1-Piperazinecarboxamide, 4-(4-chlorobenzoyl)-N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]- (9CI) (CA INDEX NAME)

10/526,178


Absolute stereochemistry.



RN 528861-31-6 CAPLUS

CN 1-Piperazinecarboxamide, 4-(3-chlorobenzoyl)-N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 528861-32-7 CAPLUS

CN 1-Piperazinecarboxamide, 4-(2-chlorobenzoyl)-N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-

10/526,178

indol-3-yl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 528861-33-8 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]hexahydro-4-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 528861-34-9 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 528861-35-0 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, 4-benzoyl-N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 528861-36-1 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[(1R,2S)-1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]hexahydro-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/526,178

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:265411 CAPLUS
DN 134:295840
TI Preparation of indolylpropanoyltetrahydroquinoline derivatives which
inhibit binding of somatostatin receptors
IN Kato, Kaneyoshi; Terauchi, Jun; Suzuki, Nobuhiro; Takekawa, Shiro
PA Tadeka Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001025228	A1	20010412	WO 2000-JP6937	20001005
	W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2386517	AA	20010412	CA 2000-2386517	20001005
	AU 2000075568	A5	20010510	AU 2000-75568	20001005
	JP 2002088079	A2	20020327	JP 2000-311723	20001005
	EP 1227090	A1	20020731	EP 2000-964676	20001005
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI	JP 1999-286939	A	19991007		
	JP 2000-215837	A	20000711		
	WO 2000-JP6937	W	20001005		
OS	MARPAT 134:295840				
IT	333952-88-8P 333952-89-9P 333953-62-1P 333953-66-5P 333953-67-6P 333953-76-7P 333953-87-0P 333953-88-1P 333954-02-2P 333954-03-3P 333954-19-1P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of indolylpropanoyltetrahydroquinoline derivs. which inhibit binding of somatostatin receptors)				
RN	333952-88-8 CAPLUS				
CN	1-Piperazinecarboxamide, N-[(1R)-2-[5-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl-(9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 333952-89-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-6-fluoro-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333953-62-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333953-66-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333953-67-6 CAPLUS

CN 1-Piperazinecarboxamide, 4-benzoyl-N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333953-76-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[5-(acetylamino)-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333953-87-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(1H-indol-2-ylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333953-88-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-[(1-methyl-1H-indol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333954-02-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3,4-dihydro-3-(1-pyrrolidinylmethyl)-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333954-03-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3,4-dihydro-3-(1-pyrrolidinylmethyl)-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 333954-19-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/526,178



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/526,178

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:672759 CAPLUS

DN 131:286420

TI Preparation of amine compounds as somatostatin receptor antagonists or agonists

IN Suzuki, Nobuhiro; Kato, Kaneyoshi; Takekawa, Shiro; Terauchi, Jun; Endo, Satoshi

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 257 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9952875	A1	19991021	WO 1999-JP1871	19990408
	W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2327695	AA	19991021	CA 1999-2327695	19990408
	AU 9952655	A1	19991101	AU 1999-52655	19990408
	JP 2000226373	A2	20000815	JP 1999-100828	19990408
	EP 1070054	A1	20010124	EP 1999-945683	19990408
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 6329389	B1	20011211	US 1999-424285	19991119
PRAI	JP 1998-96422	A	19980408		
	JP 1998-345328	A	19981204		
	WO 1999-JP1871	W	19990408		
OS	MARPAT 131:286420				
IT	246866-60-4P 246866-61-5P 246866-85-3P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(preparation of amine compds. as somatostatin receptor antagonists or agonists)				
RN	246866-60-4 CAPLUS				
CN	1-Piperazinecarboxamide, N-[(1R)-2-[3,4-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 246866-61-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[[bis(phenylmethyl)amino]methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246866-85-3 CAPLUS

CN Carbamic acid, [[1,2,3,4-tetrahydro-1-[(2R)-3-(1H-indol-3-yl)-1-oxo-2-[[4-phenyl-1-piperazinyl]carbonyl]amino]propyl]-3-quinolinyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 246866-10-4P 246866-17-1P 246866-18-2P
 246866-20-6P 246866-21-7P 246866-22-8P
 246866-54-6P 246866-55-7P 246866-58-0P
 246866-59-1P 246866-64-8P 246866-65-9P
 246866-66-0P 246866-67-1P 246866-68-2P
 246866-69-3P 246866-70-6P 246866-71-7P
 246866-72-8P 246866-75-1P 246866-86-4P
 246866-90-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amine compds. as somatostatin receptor antagonists or agonists)

RN 246866-10-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246866-17-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-(2-chlorophenyl)-N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246866-18-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246866-20-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246866-21-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246866-22-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246866-54-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3S)-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 246866-55-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3R)-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 246866-58-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3S)-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 246866-59-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[(3R)-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 246866-64-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2,3-dimethylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246866-65-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246866-66-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(2,5-dimethylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246866-67-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(3-methoxyphenyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246866-68-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246866-69-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[3,4-dihydro-3-[(methylamino)methyl]-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246866-70-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[3,4-dihydro-3-[[[phenylmethyl]amino]methyl]-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246866-71-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-(1-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246866-72-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-[(dimethylamino)methyl]-3,4-dihydro-6-methoxy-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 246866-75-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 246866-86-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[3-(aminomethyl)-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/526,178



RN 246866-90-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[(1R)-2-[7-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-4-phenyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:689265 CAPLUS

DN 129:302659

TI Preparation of pyridylpiperazines as adhesion receptor antagonists.

IN Gante, Joachim; Juraszyk, Horst; Wurziger, Hanns; Bernotat-Danielowski, Sabine; Melzer, Guido

PA Merck Patent G.m.b.H., Germany

SO Ger. Offen., 14 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19713000	A1	19981001	DE 1997-19713000	19970327
PRAI	DE 1997-19713000		19970327		
OS	MARPAT 129:302659				
IT	214201-08-8P 214201-18-0P 214201-19-1P 214201-22-6P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridylpiperazines as adhesion receptor antagonists)


RN 214201-08-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[4-(4-pyridinyl)-1-piperazinyl]carbonyl]amino]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 214201-18-0 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[[[4-(4-pyridinyl)-1-piperazinyl]carbonyl]amino]acetyl]- (9CI) (CA INDEX NAME)



RN 214201-19-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[4-(4-pyridinyl)-1-piperazinyl]carbonyl]amino]acetyl]-, monosodium salt (9CI) (CA INDEX NAME)


10/526,178



● Na

RN 214201-22-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[4-(4-piperidinyl)-1-piperazinyl]carbonyl]amino]acetyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:197358 CAPLUS

DN 128:257695

TI Preparation of modified amino acids and their use as calcitonin gene-related peptide antagonists in pharmaceutical compositions

IN Rudolf, Klaus; Eberlein, Wolfgang; Engel, Wolfhard; Pieper, Helmut; Doods, Henri; Hallermayer, Gerhard; Entzeroth, Michael; Wienen, Wolfgang

PA Karl Thomae G.m.b.H., Germany

SO PCT Int. Appl., 461 pp.

CODEN: PIXXD2

DT Patent

LA German


FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9811128	A1	19980319	WO 1997-EP4862	19970908
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	DE 19636623	A1	19980312	DE 1996-19636623	19960910
	DE 19720011	A1	19981119	DE 1997-19720011	19970514
	CA 2262818	AA	19980319	CA 1997-2262818	19970908
	AU 9741196	A1	19980402	AU 1997-41196	19970908
	AU 721035	B2	20000622		
	EP 927192	A1	19990707	EP 1997-938928	19970908
	EP 927192	B1	20040512		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9712023	A	19990831	BR 1997-12023	19970908
	JP 2000505100	T2	20000425	JP 1998-513227	19970908
	JP 3483893	B2	20040106		
	AT 266673	E	20040515	AT 1997-938928	19970908
	EE 4375	B1	20041015	EE 1999-115	19970908
	PL 190180	B1	20051130	PL 1997-331989	19970908
	NO 9901130	A	19990505	NO 1999-1130	19990309
	KR 2000044040	A	20000715	KR 1999-702008	19990310
	BG 64214	B1	20040531	BG 1999-103250	19990315
	US 6344449	B1	20020205	US 1999-254281	19991012
	HK 1021192	A1	20040430	HK 1999-105722	19991208
	US 2001036946	A1	20011101	US 2001-789391	20010221
	US 2003069231	A1	20030410	US 2002-119875	20020410
	US 2004214819	A1	20041028	US 2004-835495	20040429
PRAI	DE 1996-19636623	A	19960910		
	DE 1997-19720011	A	19970514		
	WO 1997-EP4862	W	19970908		
	US 1999-254281	A1	19991012		
	US 2001-789391	A1	20010221		
	US 2002-119875	B1	20020410		
OS	MARPAT 128:257695				
IT	204697-26-7P 204697-30-3P 205063-54-3P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of amino acids and their use as calcitonin gene-related peptide antagonists in pharmaceutical compns.)				
RN	204697-26-7 CAPLUS				

10/526,178

CN 1-Piperazinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-(1,2-dihydro-2-oxo-3-quinolinyl)-, (R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204697-30-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-(3,4-dihydro-3-oxo-2-quinoxaliny)-, (R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205063-54-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(hexahydro-1H-azepin-1-yl)-1-piperidinyl]-2-oxoethyl]-4-(2-methoxyphenyl)-, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1998:186625 CAPLUS
 DN 128:230701
 TI Preparation of varied amino acids as calcitonin gene-related peptide antagonists in pharmaceutical compositions
 IN Rudolf, Klaus; Eberlein, Wolfgang; Engel, Wolfhard; Pieper, Helmut; Doods, Henri; Hallermayer, Gerhard; Entzeroth, Michael; Wienen, Wolfgang
 PA Karl Thomae G.m.b.H., Germany
 SO Ger. Offen., 142 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19636623	A1	19980312	DE 1996-19636623	19960910
	CA 2262818	AA	19980319	CA 1997-2262818	19970908
	WO 9811128	A1	19980319	WO 1997-EP4862	19970908
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9741196	A1	19980402	AU 1997-41196	19970908
	AU 721035	B2	20000622		
	EP 927192	A1	19990707	EP 1997-938928	19970908
	EP 927192	B1	20040512		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9712023	A	19990831	BR 1997-12023	19970908
	CN 1230196	A	19990929	CN 1997-197772	19970908
	CN 1129605	B	20031203		
	JP 2000505100	T2	20000425	JP 1998-513227	19970908
	JP 3483893	B2	20040106		
	JP 2003300959	A2	20031021	JP 2003-21750	19970908
	AT 266673	E	20040515	AT 1997-938928	19970908
	EP 1440976	A1	20040728	EP 2004-3959	19970908
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	PT 927192	T	20040930	PT 1997-938928	19970908
	EE 4375	B1	20041015	EE 1999-115	19970908
	ES 2221691	T3	20050101	ES 1997-938928	19970908
	PL 190180	B1	20051130	PL 1997-331989	19970908
	ZA 9708083	A	19991217	ZA 1997-8083	19970909
	HR 970481	B1	20031031	HR 1997-481	19970909
	TW 477792	B	20020301	TW 1997-86113120	19970910
	TW 498076	B	20020811	TW 2000-89125839	19970910
	NO 9901130	A	19990505	NO 1999-1130	19990309
	BG 64214	B1	20040531	BG 1999-103250	19990315
	US 6344449	B1	20020205	US 1999-254281	19991012
	HK 1021192	A1	20040430	HK 1999-105722	19991208
PRAI	DE 1996-19636623	A	19960910		
	DE 1997-19720011	A	19970514		
	EP 1997-938928	A3	19970908		
	JP 1998-513227	A3	19970908		
	WO 1997-EP4862	W	19970908		
OS	MARPAT 128:230701				
IT	204696-44-6P 204697-26-7P 204697-30-3P				


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino acids and their use as calcitonin gene-related peptide antagonists in pharmaceutical compns.)

RN 204696-44-6 CAPLUS

CN 1-Piperazinecarboxamide, 4-(2-cyanophenyl)-N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-, (R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204697-26-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-(1,2-dihydro-2-oxo-3-quinolinyl)-, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 204697-30-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-

10/526,178

bipiperidin]-1'-yl-2-oxoethyl]-4-(3,4-dihydro-3-oxo-2-quinoxaliny)-, (R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:146698 CAPLUS

DN 128:205144

TI Di- and trisubstituted piperidine, pyrrolidine and hexahydro-1H-azepine peptide analogs promote release of growth hormone

IN Morriello, Gregori J.; Yang, Lihu; Patchett, Arthur A.

PA Merck and Co., Inc., USA

SO U.S., 81 pp., Cont.-in-part of U.S. 5,492,916.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5721250	A	19980224	US 1996-600646	19960213
	US 5492916	A	19960220	US 1994-323988	19941017
	US 5622973	A	19970422	US 1995-464982	19950605
PRAI	US 1993-173449	B2	19931223		
	US 1994-323988	A2	19941017		
	US 1994-328988	A3	19941017		

OS MARPAT 128:205144

IT 203870-92-2P 203870-93-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of di- and trisubstituted piperidine, pyrrolidine, and hexahydroazepine peptide analogs as growth hormone release promoters)

RN 203870-92-2 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[3-(1H-indol-3-yl)-1-oxo-2-[(1-piperazinylcarbonyl)amino]propyl]-3-(phenylmethyl)-, ethyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 203870-93-3 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[3-(1H-indol-3-yl)-2-[[4-methyl-1-piperazinyl)carbonyl]amino]-1-oxopropyl]-3-(phenylmethyl)-, ethyl ester, monohydrochloride, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/526,178

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

35.56

202.71

STN INTERNATIONAL LOGOFF AT 18:16:28 ON 12 DEC 2006